Success Metrics

Clinical Success Rate
61.5%

Based on 16 completed trials

Completion Rate
62%(16/26)
Active Trials
25(37%)
Results Posted
88%(14 trials)
Terminated
10(15%)

Phase Distribution

Ph phase_2
18
26%
Ph not_applicable
15
22%
Ph phase_1
21
31%
Ph phase_3
11
16%

Phase Distribution

21

Early Stage

18

Mid Stage

11

Late Stage

Phase Distribution65 total trials
Phase 1Safety & dosage
21(32.3%)
Phase 2Efficacy & side effects
18(27.7%)
Phase 3Large-scale testing
11(16.9%)
N/ANon-phased studies
15(23.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

59.3%

16 of 27 finished

Non-Completion Rate

40.7%

11 ended early

Currently Active

25

trials recruiting

Total Trials

68

all time

Status Distribution
Active(31)
Completed(16)
Terminated(11)
Other(10)

Detailed Status

Completed16
Recruiting15
Active, not recruiting10
Terminated10
unknown10
Not yet recruiting6

Development Timeline

Analytics

Development Status

Total Trials
68
Active
25
Success Rate
61.5%
Most Advanced
Phase 3

Trials by Phase

Phase 121 (32.3%)
Phase 218 (27.7%)
Phase 311 (16.9%)
N/A15 (23.1%)

Trials by Status

not_yet_recruiting69%
completed1624%
recruiting1522%
active_not_recruiting1015%
terminated1015%
unknown1015%
withdrawn11%

Recent Activity

Clinical Trials (68)

Showing 20 of 68 trialsScroll for more
NCT07030140Phase 2

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

Recruiting
NCT02837263Phase 1

PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer

Completed
NCT04194554Phase 1

A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

Active Not Recruiting
NCT07075120Phase 1

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

Recruiting
NCT07309952Phase 2

Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC

Recruiting
NCT05043857Not Applicable

Stereotactic PAncreatic RadioTherapy Adjuvant Therapy

Active Not Recruiting
NCT02839265Phase 2

FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer

Completed
NCT04262154Phase 2

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Active Not Recruiting
NCT06641791Phase 3

Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer

Recruiting
NCT04925583Phase 1

Magnetic Resonance Guided Adaptive Stereotactic Body Radiotherapy for Lung Tumors in Ultracentral Location

Active Not Recruiting
NCT07145437Not Applicable

Prostate Stereotactic Radiation and Radio-induced Lymphocyte Apoptosis for Predicting Late Toxicities in Prostate Cancer (PROSTERA)

Not Yet Recruiting
NCT02482376Phase 2

Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer

Active Not Recruiting
NCT06523634Not Applicable

Salvage Stereotactic Body Radiotherapy of the Prostate Bed for Biochemical Recurrence After Radical Prostatectomy.

Recruiting
NCT07456189Not Applicable

The Efficacy and Safety of Stereotactic Radiotherapy Bridging Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignance Patients With Extramedullary Infiltrating

Not Yet Recruiting
NCT06218420Phase 2

Evaluation of Stereotactic Body Radiotherapy as a Bridge Therapy for Hepatocellular Carcinoma Patients Enlisted for Liver Transplantation

Recruiting
NCT06048484Phase 2

Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

Recruiting
NCT07407257Not Applicable

SBRT for Liver Tumors, Liver Metastases, and Pancreatic Tumors

Completed
NCT04166734Phase 1

Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma

Terminated
NCT07381660Phase 3

SBRT Versus Surgical Resection for Small HCC

Not Yet Recruiting
NCT03505229Not Applicable

Span-C-SBRT for Pancreatic Cancer

Active Not Recruiting

Drug Details

Intervention Type
RADIATION
Total Trials
68